Clinical trials: Carcinomas
Solid Tumor, Advanced Cancer
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma).
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
- Trial name
- NCT07432295
- Testing
- Givastomig, Nivolumab, 5Fluorouracil
- Where
- 6 sites in United States, China and 1 more
- Volunteers
- 180 people
- Sponsor
- I-Mab Biopharma US Limited
Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1
Intravesical Adjuvant Electromotive Mitomycin-C
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, improving clinical efficacy in high-risk non-muscle invasive urothelial bladder cancer.
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1, Bladder Cancer Transitional Cell Grade
- Trial name
- EMDA/MMC (NCT01920269)
- Testing
- Trans-urethral resection, intravesical passive diffusion mitomycin, intravesical electromotive mitomycin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- University of Rome Tor Vergata
Breast Cancer
PBI for Breast in Situ Carcinoma of Intermediate Low Risk As Local Adjuvant Treatment
Screening and advances in breast imaging led to a continuous increase of Ductal Carcinoma in situ (DCIS) diagnosis. Whole breast radiotherapy was reported to be effective in reducing the risk of local recurrence in all analyzed…
- Trial name
- PRISCILLA (NCT05663294)
- Testing
- external beams radiotherapy, brachytherapy
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Clinico Humanitas
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist
This is a single center, prospective study to assess the efficacy and safety of using stereotactic body radiation therapy (SBRT) as bridging treatment for hepatocellular carcinoma (HCC) patients on transplant waitlist.
- Trial name
- NCT03950102
- Testing
- SBRT
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Hereditary Pancreatitis, Hereditary Pancreatic Cancer
Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.
Early detection of pre-cancerous lesions or early stage pancreatic cancer seems to have a positive impact in survival for patients with an increased genetic risk to develop pancreas cancer.
- Trial name
- NCT02078245
- Testing
- MRI
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska University Hospital
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Melanoma (Skin), Skin Cancer
Investigation of a Behavioral Substitute for Sunbathing
RATIONALE: Understanding why sunbathers use or don't use sunless tanning products may help doctors plan effective ways to prevent skin cancer caused by sunbathing.
- Trial name
- NCT00403377
- Testing
- Intervention
- Where
- United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Pancreas Metastases, Colorectal Cancer
Pancreas Resection for Colorectal Metastasis: Retrospective Study
The aim of this study is to collect data from different centres to obtain a larger case series and enable a better definition of the outcomes after pancreatic metastasectomy from primary colorectal cancer.
- Trial name
- NCT05714475
- Testing
- Pancreas surgery
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Renal Cell Carcinoma
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
- Trial name
- RECORD-3 (NCT00903175)
- Testing
- everolimus, sunitinib
- Where
- 84 sites in United States, Argentina and 17 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Non-Small Cell Lung Cancer
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
The purpose of this expanded access program (EAP) is to provide amivantamab for the treatment of participants with metastatic non-small cell lung cancer who have epidermal growth factor receptor exon 20 insertion mutations, and…
- Trial name
- NCT04599712
- Testing
- Amivantamab
- Sponsor
- Janssen Research & Development, LLC
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Hepatocellular Carcinoma, Metastatic Liver Cancers
A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
Liver cancer including primary hepatocellular carcinoma (HCC) and metastatic liver cancers is one the most common malignancies in the world. Over 10000 new cases per year are diagnosed in Taiwan.
- Trial name
- NCT02828865
- Testing
- Irreversible Electroporation (IRE) System
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence
HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC.
- Trial name
- NCT05823584
- Where
- Taiwan
- Volunteers
- 207 people
- Sponsor
- TCM Biotech International Corp.
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Esophageal Carcinoma, Neoadjuvant Therapy
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib, Toripalimab, and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell…
- Trial name
- NCT05996484
- Testing
- Toripalimab, Anlotinib hydrochloride, Albumin paclitaxel
- Volunteers
- 25 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM
- Trial name
- NCT05232552
- Testing
- Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Muscle Invasive Bladder Carcinoma
Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma
This phase I/II trial tests the feasibility of home based BCG delivery to reduce undue burden on patients undergoing treatment for non-muscle invasive bladder carcinoma.
- Trial name
- NCT07874347
- Testing
- BCG Solution, Best Practice, Cystoscopy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Neoplasms
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
This prospective randomized controlled clinical Trial will be performed in patients with locally advanced squamous cell carcinoma of the head and neck.
- Trial name
- NCT03678649
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody in patients with advanced hepatocellular carcinoma (HCC)
- Trial name
- NCT03746249
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.